Pursuing the curative blueprint for early myeloma

Mark Roschewski, Neha Korde, S. Peter Wu, Ola Landgren

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Treatment philosophies in multiple myeloma (MM) debate the relative merits of achieving the deepest possible remissions ("curative" doctrine) vs sequential delivery of antimyeloma agents ("control" doctrine). In this paper, we highlight the relevant strengths of each doctrine in the context of modern patient selection strategies, fresh biological insights on MM pathogenesis, agents with improved safety profiles, and emerging molecular and imaging tools. Paramount fundamental questions remain unanswered that require an intense research focus as we pursuea cure for this devastating disease.

Original languageEnglish (US)
Pages (from-to)486-490
Number of pages5
JournalBlood
Volume122
Issue number4
DOIs
StatePublished - Jul 25 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Pursuing the curative blueprint for early myeloma'. Together they form a unique fingerprint.

Cite this